overview of the toxicities associated with bispecific agents in multiple myeloma
Published 3 months ago • 248 plays • Length 4:58Download video MP4
Download video MP3
Similar videos
-
1:29
managing toxicities associated with immunotherapy in multiple myeloma
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:02
novel agents in multiple myeloma: considering toxicity and side effects
-
1:53
the future of multiple myeloma treatment
-
0:59
defining the origins of multiple myeloma
-
2:33
the effect of lymphodepleting agents on rate and severity of toxicities following car-t infusion
-
58:00
know your myeloma immunotherapy: teclistamab and other bispecifics
-
5:59
what is hrmm (high-risk multiple myeloma)? #myeloma
-
6:31
a meta-analysis assessing the safety of cytoreductive therapies in younger patients with pv
-
2:47
clinical and prognostic implications of wt1 mutations in de novo and r/r aml
-
6:58
current treatments and sequencing of agents in multiple myeloma
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma
-
4:13
real-world study determining the safety and efficacy of teclistamab in r/r multiple myeloma
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:43
real-world outcomes of teclistamab for r/r multiple myeloma
-
1:33
advances being made in high-risk smoldering myeloma: ongoing trials & promising agents
-
1:56
cevostamab (bfcr4350a): a novel bispecific antibody in r/r myeloma therapy
-
1:23
investigating bispecific antibodies in high-risk smoldering myeloma: the immunoprism platform study
-
4:23
proteasome inhibitors in myeloma treatment